Barreleye, Inc.

Based in South Korea, Barreleye, Inc. operates as a provider of AI-assisted ultrasound solutions, enhancing diagnostic precision in medical imaging for various conditions, including cardiac and breast assessments. Founded in 2021 and headquartered in Seoul, South Korea, Barreleye, Inc. specializes in quantitative ultrasound solutions.

The company has completed one deal, raising KRW 14 billion in Series A funding on November 13, 2025. Barreleye has not undergone any significant pivots in its business model and does not have any known subsidiaries. The founder's background is currently unspecified. Barreleye is recognized as a global leader in quantitative ultrasound solutions, primarily focusing on AI-assisted ultrasound image analysis.

The company's core offerings include advanced technologies for breast, cardiac, hepatic, and thyroid assessments. These products leverage artificial intelligence to enhance diagnostic accuracy and streamline the imaging process, ultimately aiming to improve patient outcomes in various medical fields. The solutions are designed to cater to healthcare providers, including hospitals and diagnostic centers, which serve patients requiring precise imaging for conditions such as breast cancer and liver disease. Barreleye distributes its products across multiple international markets, ensuring its advanced ultrasound technology is accessible to a diverse clientele.

Barreleye's revenue model is centered around B2B transactions, engaging primarily with healthcare institutions that utilize their ultrasound solutions. The company structures its offerings through direct sales and partnerships, facilitating the implementation of its products in medical facilities. Clients typically enter into agreements that may include one-time purchases of technology or ongoing service contracts for software and maintenance. Specific pricing plans for Barreleye's flagship products, which include the Vis-BUS and Int-BUS technologies, are tailored to individual customer needs based on facility requirements and usage volume.

This structured pricing strategy allows Barreleye to maintain a steady revenue stream while fostering long-term relationships with healthcare providers. In November 2025, Barreleye, Inc. raised KRW 14 billion in Series A funding from other unspecified investors. The company plans to utilize this funding for its global expansion initiatives, focusing on introducing new products and entering new international markets.

Specific details regarding upcoming product launches or targeted regions for expansion have not been disclosed.